.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,649,659

« Back to Dashboard

Claims for Patent: 6,649,659

Title: Atovaquone pharmaceutical compositions
Abstract:The invention relates to a process for the production of microfluidized particles of atovaquone having improved bioavailability.
Inventor(s): Dearn; Alan Roy (Dartford, GB)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:09/411,381
Patent Claims: 1. Small particles of atovaquone wherein at least 90% of the particles of atovaquone have a volume diameter in the range 0.1-3 .mu.m.

2. Small particles of atovaquone wherein the particles of atovaquone have been microfluidized.

3. Microfluidized particles of atovaquone wherein at least 90% of the microfluidized particles of atovaquone have a volume diameter in the range 0.1-3 .mu.m.

4. A pharmaceutical composition comprising particles of atovaquone and one or more pharmaceutically acceptable carriers therefor wherein at least 90% of the particles have a volume diameter in the range of 0.1-3 .mu.m.

5. A pharmaceutical composition according to claim 4, wherein the particles are Microfluidized particles.

6. A pharmaceutical composition according to claim 4 or claim 5 in suspension.

7. A pharmaceutical composition according to claim 4 wherein the pharmaceutically acceptable carriers include a suspending agent.

8. A pharmaceutical composition according to claim 4 in suspension wherein the pharmaceutically acceptable carriers include a suspending agent.

9. A pharmaceutical composition according to claim 7, wherein the suspending agent is xanthan gum.

10. A pharmaceutical composition according to claim 8, wherein the suspending agent is xanthan gum.

11. A method for the treatment and/or prophylaxis of protozoal infections in mammals which comprises administering to said mammals an effective amount of particles of atovaquone and one or more pharmaceutically acceptable carrier therefor wherein at least 90% of the particles have a volume diameter in the range of 0.1-3 .mu.m.

12. The method according to claim 11 wherein said protozoal infection is caused by Pneumocystis carinii.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc